<SEC-DOCUMENT>0001140361-26-026601.txt : 20260626
<SEC-HEADER>0001140361-26-026601.hdr.sgml : 20260626
<ACCEPTANCE-DATETIME>20260626172447
ACCESSION NUMBER:		0001140361-26-026601
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260626
DATE AS OF CHANGE:		20260626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apogee Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001974640
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				934958665
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41740
		FILM NUMBER:		261130618

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 17, SUITE 102B
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		650-394-5230

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 17, SUITE 102B
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Apogee Therapeutics, LLC
		DATE OF NAME CHANGE:	20230420
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ef20076957_defa14a.htm
<DESCRIPTION>DEFA 14A
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div style="font-size: 14pt;">
      <div style="text-align: center; font-weight: bold;">UNITED STATES</div>
    </div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div><br>
    </div>
    <div style="font-size: 18pt;">
      <div style="text-align: center; font-weight: bold;">SCHEDULE 14A</div>
    </div>
    <div style="text-align: center; font-weight: bold;">Proxy Statement Pursuant to Section 14(a) of the</div>
    <div style="text-align: center; font-weight: bold;">Securities Exchange Act of 1934</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div><br>
    </div>
    <div>Filed by the Registrant&#8194;&#9746;</div>
    <div><br>
    </div>
    <div>Filed by a party other than the Registrant&#8194;&#9744;</div>
    <div><br>
    </div>
    <div>Check the appropriate box:</div>
    <div> <br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdae0df525e7241449a5700482c3aeb1f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="color: #000000;">&#9744;</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: #000000;">Preliminary Proxy Statement</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 12pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zfa9450538836418e9cdb4b4d3a1cfaba" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="color: #000000;">&#9744;</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: #000000; font-weight: bold;">Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 12pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z54f7cb6e0650413ba0efadb05551a32a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="color: #000000;">&#9744;</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: #000000;">Definitive Proxy Statement</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 12pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9119df4e690a4554b89ef06eae2534e4" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="color: #000000;">&#9744;</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: #000000;">Definitive Additional Materials</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 12pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zf7145fc1d63f4ba6be894b43268bcce0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="color: #000000;">&#9746;</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: #000000;">Soliciting Material Pursuant to &#167;240.14a-12</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 24pt; font-weight: bold;">APOGEE THERAPEUTICS, INC.</div>
    <div style="text-align: center; font-weight: bold;">(Name of Registrant as Specified in its Charter)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>
    <div><br>
    </div>
    <div>Payment of Filing Fee (Check the appropriate box):</div>
    <div> <br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc3ed3441d91149edbce3736255cefdaa" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="color: #000000;">&#9746;</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: #000000;">No fee required.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc5a0669e1ceb4debb125ff0826ef49e8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="color: #000000;">&#9744;</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: #000000;">Fee paid previously with preliminary materials.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze3a5681d6d764ec897f7d304e199fe4c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;"><font style="color: #000000;">&#9744;</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="color: #000000;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div> <br>
    </div>
    <div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">This Schedule 14A relates solely to preliminary communications made prior to furnishing security holders of Apogee Therapeutics, Inc. (&#8220;<u>Apogee</u>&#8221; or the &#8220;<u>Company</u>&#8221;) with a proxy statement related to a
      proposed transaction in which Andor Merger Co. (&#8220;<u>Merger Sub</u>&#8221;), a Delaware corporation and wholly owned subsidiary of Andor LLC (&#8220;<u>Parent</u>&#8221;), a Delaware limited liability company and a wholly owned subsidiary of AbbVie Inc. (&#8220;<u>AbbVie</u>&#8221;),











      will merge with and into the Company (the &#8220;<u>Merger</u>&#8221;), with the Company surviving the Merger as a wholly owned subsidiary of Parent, upon the terms and subject to the conditions set forth in the Agreement and Plan of Merger, dated June 18, 2026,
      among Parent, Merger Sub, the Company, and solely for the limited purposes set forth therein, AbbVie.</div>
    <div><br>
    </div>
    <div>This Schedule 14A filing consists of the following documents relating to the Merger:</div>
    <div><br>
    </div>
    <div style="margin-left: 27pt;">Exhibit 99.1: Principal Investigator Email</div>
    <div><br>
    </div>
    <div style="text-align: center; margin-left: 27pt;">*&#160;&#160; *&#160;&#160; *</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">Cautionary Statement Regarding Forward-Looking Statements</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This communication contains statements that constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E
      of the Securities Exchange Act of 1934, each as amended. All statements other than statements of historical fact, including statements regarding market and industry prospects and future results of operations or financial position made in this
      communication are forward-looking. In many cases, you can identify forward-looking statements by terminology, such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the
      negative of such terms and other comparable terminology. Statements in this communication that are forward-looking may include, but are not limited to, statements regarding the benefits of the proposed acquisition of Apogee Therapeutics, Inc.
      (&#8220;Apogee&#8221;) by AbbVie Inc. (&#8220;AbbVie&#8221;) and the associated integration plans, anticipated future operating performance and results of Apogee, the expected accretion to AbbVie&#8217;s adjusted diluted earnings per share beginning in 2032, the expected timing
      of the closing of the proposed acquisition and other transactions contemplated by the merger agreement governing the proposed acquisition (the &#8220;Merger Agreement&#8221;), and the potential of zumilokibart (APG777) and other Apogee&#8217;s pipeline assets.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">There may also be other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Readers are cautioned
      that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are difficult to predict and are generally outside Apogee&#8217;s control, that could cause actual performance or results
      to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the occurrence of any event, change or other circumstance that could give rise to
      the right of Apogee or AbbVie or both of them to terminate the Merger Agreement, including circumstances requiring a party to pay the other party a termination fee pursuant to the Merger Agreement; the failure to obtain applicable regulatory or
      Apogee stockholder approval in a timely manner or otherwise; the risk that the proposed acquisition may not close in the anticipated timeframe or at all due to one or more of the other closing conditions to the transaction not being satisfied or
      waived; the possibility of competing acquisition proposals for Apogee; the risk that there may be unexpected costs, charges or expenses resulting from the proposed acquisition; risks related to the ability of Apogee and AbbVie to successfully
      integrate the businesses and the possibility that such integration may be more difficult, time consuming or costly than expected; risks that the proposed transaction disrupts Apogee&#8217;s or AbbVie&#8217;s current plans and operations; the risk that certain
      restrictions during the pendency of the proposed transaction may impact Apogee&#8217;s ability to pursue certain business opportunities or strategic transactions; risks related to disruption of each company&#8217;s management&#8217;s time and attention from ongoing
      business operations due to the proposed transaction; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Apogee&#8217;s and/or AbbVie&#8217;s common stock, credit ratings or operating results;
      the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Apogee and AbbVie to retain and hire key personnel, to retain customers and to maintain relationships with each of their respective business
      partners, suppliers and customers and on their respective operating results and businesses generally; the risk of litigation that could be instituted against the parties to the Merger Agreement or their respective directors, managers or officers
      and/or regulatory actions related to the proposed acquisition, including the effects of any outcomes related thereto; the risk that zumilokibart (APG777) or APG273 and other Apogee&#8217;s pipeline assets may not demonstrate the anticipated success,
      safety, or efficacy in ongoing or future clinical trials; the risk that positive Phase 2 and Phase 1b interim results for zumilokibart (APG777) may not be predictive of results in later-stage or larger clinical trials; challenges to intellectual
      property; adverse litigation or government action; competition from other products; difficulties inherent in the research and development process; risks related to unpredictable and severe or catastrophic events, including but not limited to acts of
      terrorism, war or hostilities, cyber attacks, or the impact of any pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on Apogee&#8217;s or AbbVie&#8217;s business, financial condition and results of operations, as well as
      the response thereto by each company&#8217;s management; and other business effects, including the effects of industry, market, economic, political or regulatory conditions.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">Also, AbbVie&#8217;s and Apogee&#8217;s actual results may differ materially from those contemplated by the forward-looking statements for a number of additional reasons as described in AbbVie&#8217;s and Apogee&#8217;s filings with the
      Securities and Exchange Commission (the &#8220;SEC&#8221;), including those set forth in the Risk Factors section and under any &#8220;Forward-Looking Statements&#8221; or similar heading in AbbVie&#8217;s and Apogee&#8217;s most recently filed Annual Report on Form 10-K filed on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm">February 20, 2026</a>, and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1974640/000197464026000002/apge-20251231.htm">March 2, 2026</a>,
      respectively, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">AbbVie and Apogee have based these forward-looking statements on their current expectations and projections about future events. Although the parties believe that the assumptions on which the forward-looking statements
      contained herein are based are reasonable, any of those assumptions could prove to be inaccurate. As a result, the forward-looking statements based upon those assumptions also could be incorrect. Except to the extent required by law, AbbVie and
      Apogee undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">Additional Information and Where to Find It</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This communication is being made in respect of the proposed transaction involving Apogee and AbbVie. A meeting of the stockholders of Apogee will be announced as promptly as practicable to seek Apogee stockholder
      approval in connection with the proposed transaction. Apogee intends to file relevant materials with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statement will be mailed to
      Apogee&#8217;s stockholders. This communication is not a substitute for the proxy statement or any other document that may be filed by Apogee with the SEC.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">BEFORE MAKING ANY DECISION, APOGEE STOCKHOLDERS ARE URGED TO CAREFULLY READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO
      BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Any vote in respect of resolutions to be proposed at Apogee&#8217;s stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the
      information contained in Apogee&#8217;s proxy statement. You will be able to obtain a free copy of the proxy statement and other related documents (when available) filed by Apogee with the SEC at the website maintained by the SEC at www.sec.gov or by
      accessing the Investors section of Apogee&#8217;s website at https://investors.apogeetherapeutics.com.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">No Offer or Solicitation</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This communication is for informational purposes only and is not intended to, and does not constitute or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire,
      subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any
      jurisdiction in contravention of applicable law.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">Participants in the Solicitation</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Apogee, AbbVie and their respective directors and executive officers and certain of their employees may be deemed to be participants in the solicitation of proxies from Apogee&#8217;s stockholders in connection with the
      proposed transaction. Information regarding Apogee&#8217;s directors and executive officers is set forth under the captions &#8220;Proposal 1: Election of Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Executive Officers,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Certain Information
      About Our Common Stock&#8221; in the definitive proxy statement for Apogee&#8217;s 2026 Annual Meeting of Stockholders, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1974640/000119312526177342/apge-20260424.htm"><font style="color: #0000FF;"><u>April 24, 2026</u></font></a>, and in Apogee&#8217;s Current Reports on Form 8-K, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1974640/000119312526177288/apge-20260421.htm"><font style="color: #0000FF;"><u>April 24, 2026</u></font></a>, and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1974640/000119312526269650/apge-20260609.htm">June 12, 2026</a>. Information regarding AbbVie&#8217;s directors and executive
      officers is set forth under the captions &#8220;Information Concerning Director Nominees,&#8221; &#8220;The Board of Directors and its Committees,&#8221; &#8220;Director Compensation,&#8221; &#8220;Securities Ownership&#8221; and &#8220;Executive Compensation&#8221; in the definitive proxy statement for
      AbbVie&#8217;s 2026 Annual Meeting of Stockholders, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htm"><font style="color: #0000FF;"><u>March 23, 2026</u></font></a>, and in
      AbbVie&#8217;s Current Report on Form 8-K, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1551152/000110465926059484/tm2614276d1_8k.htm"><font style="color: #0000FF;"><u>May 12, 2026</u></font></a>. To the extent holdings
      of Apogee&#8217;s securities and AbbVie&#8217;s securities by their respective directors or executive officers have changed since the amounts set forth in such filings, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on
      Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. These documents may be obtained free of charge from the SEC&#8217;s website at www.sec.gov or by accessing the Investors section of Apogee&#8217;s website at
      https://investors.apogeetherapeutics.com and the Investors section of AbbVie&#8217;s website at https://investors.abbvie.com. Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed
      transaction will be included in the proxy statement that Apogee expects to file in connection with the proposed transaction and other relevant materials Apogee may file with the SEC.</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: right;"> <font style="font-weight: bold;">Exhibit 99.1</font><br>
    </div>
    <div style="text-align: right;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div>
      <div>
        <div style="font-weight: bold;">Principal Investigator Email</div>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 1px; width: 100%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div><font style="font-weight: bold;">Subject: </font>An important Update on the Future of Apogee Therapeutics</div>
      <div><br>
      </div>
      <div>[Dear NAME / INSERT CUSTOMARY GREETING],</div>
      <div><br>
      </div>
      <div>On June 22, 2026 we <u>announced</u>&#160;(<u>press release</u>) that Apogee Therapeutics has entered into an agreement to be acquired by AbbVie. This is an important transaction for our company as we advance our vision to reshape the standard of
        care for people living with inflammatory and immunological conditions.</div>
      <div><br>
      </div>
      <div>We are incredibly proud of all that we have achieved since our founding just four years ago. With compelling clinical data supporting zumilokibart and a differentiated portfolio, we have a strong foundation to move ahead independently. At the
        same time, our decisions have always been grounded in a fundamental belief: <font style="font-weight: bold;">the most important thing we can do is get zumilokibart and the other therapies in our pipeline to as many patients as possible, as quickly
          as possible</font>. Our commitment to that goal was the driving force behind our decision to enter into this agreement with AbbVie.</div>
      <div><br>
      </div>
      <div>As you may know, AbbVie is a global leader in immunology with extensive Phase 3 development and commercial capabilities. Combining our portfolio with AbbVie&#8217;s scale, resources and experience will enable us to reach more patients around the
        world. We are confident this is the right path forward for Apogee and the patients we seek to serve.</div>
      <div><br>
      </div>
      <div>In terms of next steps, we expect the transaction to close in the third quarter of 2026, subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals. Until then, Apogee will continue to
        operate as an independent company, and it remains business as usual.</div>
      <div><br>
      </div>
      <div><font style="font-weight: bold;">Our teams are as focused as ever on advancing our work to improve the lives of people living with I&amp;I conditions. </font>We are continuing to advance our clinical and development programs, and your Apogee
        contacts will remain the same as you see here. We will keep you informed as we move ahead and, if you have any questions in the meantime, please don&#8217;t hesitate to reach out.</div>
      <div><br>
      </div>
      <div>Thank you for your ongoing partnership and support of Apogee.</div>
      <div><br>
      </div>
      <div>Sincerely,</div>
      <div><br>
      </div>
      <div>[NAME</div>
      <div>TITLE]</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">Cautionary Statement Regarding Forward-Looking Statements</div>
      <div><br>
      </div>
      <div style="text-align: justify;">This communication contains statements that constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section
        21E of the Securities Exchange Act of 1934, each as amended. All statements other than statements of historical fact, including statements regarding market and industry prospects and future results of operations or financial position made in this
        communication are forward-looking. In many cases, you can identify forward-looking statements by terminology, such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the
        negative of such terms and other comparable terminology. Statements in this communication that are forward-looking may include, but are not limited to, statements regarding the benefits of the proposed acquisition of Apogee Therapeutics, Inc.
        (&#8220;Apogee&#8221;) by AbbVie Inc. (&#8220;AbbVie&#8221;) and the associated integration plans, anticipated future operating performance and results of Apogee, the expected accretion to AbbVie&#8217;s adjusted diluted earnings per share beginning in 2032, the expected timing
        of the closing of the proposed acquisition and other transactions contemplated by the merger agreement governing the proposed acquisition (the &#8220;Merger Agreement&#8221;), and the potential of zumilokibart (APG777) and other Apogee&#8217;s pipeline assets.</div>
      <div><br>
      </div>
      <div style="text-align: right;">Page 1 of 3<br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify;">There may also be other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Readers are cautioned
        that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are difficult to predict and are generally outside Apogee&#8217;s control, that could cause actual performance or results
        to differ materially from those expressed in, or implied or projected by, the forward-looking statements. Such risks and uncertainties include, but are not limited to: the occurrence of any event, change or other circumstance that could give rise
        to the right of Apogee or AbbVie or both of them to terminate the Merger Agreement, including circumstances requiring a party to pay the other party a termination fee pursuant to the Merger Agreement; the failure to obtain applicable regulatory or
        Apogee stockholder approval in a timely manner or otherwise; the risk that the proposed acquisition may not close in the anticipated timeframe or at all due to one or more of the other closing conditions to the transaction not being satisfied or
        waived; the possibility of competing acquisition proposals for Apogee; the risk that there may be unexpected costs, charges or expenses resulting from the proposed acquisition; risks related to the ability of Apogee and AbbVie to successfully
        integrate the businesses and the possibility that such integration may be more difficult, time consuming or costly than expected; risks that the proposed transaction disrupts Apogee&#8217;s or AbbVie&#8217;s current plans and operations; the risk that certain
        restrictions during the pendency of the proposed transaction may impact Apogee&#8217;s ability to pursue certain business opportunities or strategic transactions; risks related to disruption of each company&#8217;s management&#8217;s time and attention from ongoing
        business operations due to the proposed transaction; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Apogee&#8217;s and/or AbbVie&#8217;s common stock, credit ratings or operating results;
        the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Apogee and AbbVie to retain and hire key personnel, to retain customers and to maintain relationships with each of their respective business
        partners, suppliers and customers and on their respective operating results and businesses generally; the risk of litigation that could be instituted against the parties to the Merger Agreement or their respective directors, managers or officers
        and/or regulatory actions related to the proposed acquisition, including the effects of any outcomes related thereto; the risk that zumilokibart (APG777) or APG273 and other Apogee&#8217;s pipeline assets may not demonstrate the anticipated success,
        safety, or efficacy in ongoing or future clinical trials; the risk that positive Phase 2 and Phase 1b interim results for zumilokibart (APG777) may not be predictive of results in later-stage or larger clinical trials; challenges to intellectual
        property; adverse litigation or government action; competition from other products; difficulties inherent in the research and development process; risks related to unpredictable and severe or catastrophic events, including but not limited to acts
        of terrorism, war or hostilities, cyber attacks, or the impact of any pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on Apogee&#8217;s or AbbVie&#8217;s business, financial condition and results of operations, as well
        as the response thereto by each company&#8217;s management; and other business effects, including the effects of industry, market, economic, political or regulatory conditions.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Also, AbbVie&#8217;s and Apogee&#8217;s actual results may differ materially from those contemplated by the forward-looking statements for a number of additional reasons as described in AbbVie&#8217;s and Apogee&#8217;s filings with the
        Securities and Exchange Commission (the &#8220;SEC&#8221;), including those set forth in the Risk Factors section and under any &#8220;Forward-Looking Statements&#8221; or similar heading in AbbVie&#8217;s and Apogee&#8217;s most recently filed Annual Report on Form 10-K filed on
        February 20, 2026 and March 2, 2026, respectively, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">AbbVie and Apogee have based these forward-looking statements on their current expectations and projections about future events. Although the parties believe that the assumptions on which the forward-looking
        statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate. As a result, the forward-looking statements based upon those assumptions also could be incorrect. Except to the extent required by law,
        AbbVie and Apogee undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</div>
      <div><br>
      </div>
      <div style="text-align: right;">Page 2 of 3</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; font-weight: bold;">Additional Information and Where to Find It</div>
      <div><br>
      </div>
      <div style="text-align: justify;">This communication is being made in respect of the proposed transaction involving Apogee and AbbVie. A meeting of the stockholders of Apogee will be announced as promptly as practicable to seek Apogee stockholder
        approval in connection with the proposed transaction. Apogee intends to file relevant materials with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. The definitive proxy statement will be mailed
        to Apogee&#8217;s stockholders. This communication is not a substitute for the proxy statement or any other document that may be filed by Apogee with the SEC.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">BEFORE MAKING ANY DECISION, APOGEE STOCKHOLDERS ARE URGED TO CAREFULLY READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED OR
        TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Any vote in respect of resolutions to be proposed at Apogee&#8217;s stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the
        information contained in Apogee&#8217;s proxy statement. You will be able to obtain a free copy of the proxy statement and other related documents (when available) filed by Apogee with the SEC at the website maintained by the SEC at <u>www.sec.gov</u>
        or by accessing the Investors section of Apogee&#8217;s website at <u>https://investors.apogeetherapeutics.com</u>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">No Offer or Solicitation</div>
      <div><br>
      </div>
      <div style="text-align: justify;">This communication is for informational purposes only and is not intended to, and does not constitute or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise
        acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities
        in any jurisdiction in contravention of applicable law.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Participants in the Solicitation</div>
      <div><br>
      </div>
      <div>Apogee, AbbVie and their respective directors and executive officers and certain of their employees may be deemed to be participants in the solicitation of proxies from Apogee&#8217;s stockholders in connection with the proposed transaction.
        Information regarding Apogee&#8217;s directors and executive officers is set forth under the captions &#8220;Proposal 1: Election of Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Executive Officers,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Certain Information About Our Common
        Stock&#8221; in the definitive proxy statement for Apogee&#8217;s 2026 Annual Meeting of Stockholders, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1974640/000119312526177342/apge-20260424.htm">April 24, 2026</a>, and in
        Apogee&#8217;s Current Reports on Form 8-K, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1974640/000119312526177288/apge-20260421.htm">April 24, 2026</a> and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001974640/000119312526269650/apge-20260609.htm">June 12, 2026</a>. Information regarding AbbVie&#8217;s directors and executive officers is set forth under the captions &#8220;Information Concerning
        Director Nominees,&#8221; &#8220;The Board of Directors and its Committees,&#8221; &#8220;Director Compensation,&#8221; &#8220;Securities Ownership&#8221; and &#8220;Executive Compensation&#8221; in the definitive proxy statement for AbbVie&#8217;s 2026 Annual Meeting of Stockholders, filed with the SEC on
        <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1551152/000110465926033387/abbv-20260508xdef14a.htm">March 23, 2026</a>, and in AbbVie&#8217;s Current Report on Form 8-K, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1551152/000110465926059484/tm2614276d1_8k.htm">May 12, 2026</a>. To the extent holdings of Apogee&#8217;s securities and AbbVie&#8217;s securities by their respective directors or executive officers have
        changed since the amounts set forth in such filings, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Beneficial Ownership on Form 4 filed with the SEC. These documents may be
        obtained free of charge from the SEC&#8217;s website at <u>www.sec.gov</u> or by accessing the Investors section of Apogee&#8217;s website at <u>https://investors.apogeetherapeutics.com</u> and the Investors section of AbbVie&#8217;s
        website at <u>https://investors.abbvie.com</u>. Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed transaction will be included in the proxy statement that
        Apogee expects to file in connection with the proposed transaction and other relevant materials Apogee may file with the SEC.</div>
      <div><br>
      </div>
      <div style="text-align: right;">Page 3 of 3</div>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <!--PROfilePageNumberReset%Num%1%%%--></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
